Serum salusin-α and salusin-β levels in patients with behcet’s disease


Erden I., Demir B., Uçak H., Cicek D., BAKAR DERTLİOĞLU S., Aydin S.

European Journal of Dermatology, cilt.24, sa.5, ss.577-582, 2014 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24 Sayı: 5
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1684/ejd.2014.2397
  • Dergi Adı: European Journal of Dermatology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.577-582
  • Anahtar Kelimeler: Behcet's Disease, salusin-alpha, salusin-beta, metabolic syndrome, insulin resistance
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Background: Behcet’s disease (BD) is a chronic, relapsing, systemic vasculitis of unknown etiology. There is an increased predisposition to insulin resistance and metabolic syndrome (MetS) in BD patients. Objective: The aim of this study was to determine serum salusin-α and salusin-β levels in BD patients and healthy controls and to investigate their association with MetS. Patients and Methods: Twenty-five BD patients and 25 healthy controls were included in the study. Salusin-α and salusin-β levels were measured in blood samples using ELISA. In addition, BD patients and healthy controls were evaluated in terms of MetS. Results: The mean serum salusin-α level in BD patients was significantly lower compared to healthy controls (p = 0.03), whereas the mean serum salusin-β level in BD patients was significantly higher compared to healthy controls (p = 0.03). The mean serum salusin-level was significantly lower in BD patients with MetS compared to BD patients without MetS (p = 0.04). Conclusions: Serum salusin-α level (an anti-atherogenic molecule)was lower, while serum salusin-β level (a pro-atherogenic molecule) was higher in BD patients. We consider that the decrease in salusin-α and the increase in salusin-β levels contribute to the development of MetS.